Her2
Untracked preview. This is not a tracked Signal Bureau entity — the page is generated on request from live coverage search, is not indexed, and carries no editorial curation. Tracked entities live on the Wire.
Coverage of Her2 is accelerating : 12 signals on the latest tracked day, up 200% from its three-week baseline of 4, across 6 domains (up from 4 a week ago).
If Her2 matters to your work, the information environment around it is moving faster than its own baseline — worth a daily look while the build lasts.
What’s changed
6 of the last 7 tracked days ran above the three-week baseline — a sustained move, not a one-day spike.
- FDA grants accelerated approval to Bayer’s sevabertinib for HER2-mutant NSCLC · Voice of Healthcare · 2026-09-11
- Predictors of pCR to Neoadjuvant THP Explored in HER2-Positive Breast Cancer · The ASCO Post · 2026-09-04
- Phase III OPTIMA Trial: Many Patients With ER-Positive, HER2-Negative Breast Cancer May Be Able to Avoid Chemotherapy · The ASCO Post · 2026-09-04
- Study Evaluates Chemotherapy-Free Quadruplet in HR-Positive, HER2-Positive Metastatic Breast Cancer · The ASCO Post · 2026-08-27
- FDA Approves Zanidatamab Combination Regimens for HER2 Gastric GEJ or Esophageal Cancer · The ASCO Post · 2026-08-25
- [APPROVAL] FDA approves imlunestrant in combination with abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer · FDA Drug News · 2026-09-19 · usually covers Pharma Regulatory
What the reporting says
Across 92 tracked stories from 29 outlets, reporting on Her2 most often describes regulatory approvals (26), military action (2), elections (2), acquisition (1), funding rounds (1).
It shows up alongside Breast Cancer (60), Her2 Negative (36), Overall Survival (33), Egfr (24), Her2 Positive (24), Lung Cancer (23), Colorectal Cancer (33), Immunotherapy (30).
Two steps out: FDA (through Breast Cancer, 54 shared stories on the weaker link); AI (through Colorectal Cancer, 33 shared stories on the weaker link); ASCO (through Overall Survival, 33 shared stories on the weaker link); Braf (through Colorectal Cancer, 33 shared stories on the weaker link).
Tracked since Mar 22, with coverage on 48 separate days — concentrated in Society News and Oncology.